GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anebulo Pharmaceuticals Inc (NAS:ANEB) » Definitions » PB Ratio

Anebulo Pharmaceuticals (Anebulo Pharmaceuticals) PB Ratio : 11.80 (As of May. 05, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Anebulo Pharmaceuticals PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-05), Anebulo Pharmaceuticals's share price is $2.95. Anebulo Pharmaceuticals's Book Value per Share for the quarter that ended in Dec. 2023 was $0.25. Hence, Anebulo Pharmaceuticals's PB Ratio of today is 11.80.

The historical rank and industry rank for Anebulo Pharmaceuticals's PB Ratio or its related term are showing as below:

ANEB' s PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 13.2
Current: 11.8

During the past 4 years, Anebulo Pharmaceuticals's highest PB Ratio was 13.20. The lowest was 0.00. And the median was 0.00.

ANEB's PB Ratio is ranked worse than
91.62% of 1312 companies
in the Biotechnology industry
Industry Median: 2.5 vs ANEB: 11.80

During the past 12 months, Anebulo Pharmaceuticals's average Book Value Per Share Growth Rate was -58.70% per year.

Back to Basics: PB Ratio


Anebulo Pharmaceuticals PB Ratio Historical Data

The historical data trend for Anebulo Pharmaceuticals's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anebulo Pharmaceuticals PB Ratio Chart

Anebulo Pharmaceuticals Annual Data
Trend Jun20 Jun21 Jun22 Jun23
PB Ratio
- 7.44 8.06 5.68

Anebulo Pharmaceuticals Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.01 5.74 5.68 9.40 9.68

Competitive Comparison of Anebulo Pharmaceuticals's PB Ratio

For the Biotechnology subindustry, Anebulo Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anebulo Pharmaceuticals's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anebulo Pharmaceuticals's PB Ratio distribution charts can be found below:

* The bar in red indicates where Anebulo Pharmaceuticals's PB Ratio falls into.



Anebulo Pharmaceuticals PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Anebulo Pharmaceuticals's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=2.95/0.25
=11.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Anebulo Pharmaceuticals  (NAS:ANEB) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Anebulo Pharmaceuticals PB Ratio Related Terms

Thank you for viewing the detailed overview of Anebulo Pharmaceuticals's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Anebulo Pharmaceuticals (Anebulo Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
1017 Ranch Road 620 South, Suite 107, Lakeway, TX, USA, 78734
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company. It is developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.
Executives
Bimal R. Shah director C/O SPECTRUM PHARMACEUTICALS, 11500 SOUTH EASTER AVENUE, SUITE 240, HENDERSON NV 89052
Richard Anthony Cunningham, director, officer: Chief Executive Officer ONE KENDALL SQUARE, BUILDING 200 SUITE 2, CAMBRIDGE MA 02139
Dan George officer: Chief Financial Officer 1412 62ND STREET, EMERYVILLE CA 94608
Sandra A. Gardiner officer: Acting Chief Financial Officer CUTERA, INC., 3240 BAYSHORE BOULEVARD, BRISBANE CA 94005
Kenneth C Cundy officer: Chief Scientific Officer 1455 ADAMS DRIVE, SUITE 2050, MENLO BUSINESS PARK, MENLO PARK CA 94025
Nathaniel Calloway director C/O ANEBULO PHARMACEUTICALS, INC., 1415 RANCH ROAD 620 SOUTH, SUITE 201, LAKEWAY TX 78734
Simon Allen director, officer: Chief Executive Officer C/O AMBRX, INC., 10975 N. TORREY PINES RD., LA JOLLA CA 92037
Aron R. English director, 10 percent owner 1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107
Kenneth Lin director PO BOX 1005, LOS ALTOS CA 94022
Karah Herdman Parschauer director 60 LEVERONI COURT, NOVATO CA 94949
22nw Fund, Lp 10 percent owner 1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107
Joseph F. Lawler director, 10 percent owner 2110 RANCH ROAD 620 S, #341732, LAKEWAY TX 78734
Areta Kupchyk director C/O ANEBULO PHARMACEUTICALS, INC., 1415 RANCH ROAD 620 SOUTH, SUITE 201, LAKEWAY TX 78734
Jason Aryeh director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
22nw, Lp 10 percent owner, other: See Explanation of Response 590 1ST AVE S, UNIT C1, SEATTLE WA 98104

Anebulo Pharmaceuticals (Anebulo Pharmaceuticals) Headlines

From GuruFocus